Compare Stocks

→ A new way to collect income from stocks (From DTI) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALDX Aldeyra Therapeutics	$3.94 +0.8%	$3.62	$1.42 ▼ $11.97	$232.07M	1.51	585,545 shs	570,390 shs
CALA Calithera Biosciences	$0.03	$0.02	$0.01 ▼ $0.50	$141K	-0.17	1,560 shs	583 shs
CSU Capital Senior Living		$31.66	$8.62 ▼ $58.94	$73.49M	2.15	32,471 shs	77 shs
HOOK Hookipa Pharma	$0.85 +10.4%	$0.74	$0.41 ▼ $2.05	$75.70M	1.02	574,477 shs	10.42 million shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALDX Aldeyra Therapeutics	+0.77%	-0.76%	+36.81%	+29.61%	-56.61%
CALA Calithera Biosciences	0.00%	-27.50%	+45.00%	-3.33%	-27.50%
CSU Capital Senior Living	0.00%	0.00%	0.00%	0.00%	0.00%
HOOK Hookipa Pharma	+11.11%	+11.48%	+20.98%	+19.72%	-10.62%

Claim Your Complimentary Bitcoin Reward (Ad)

Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.

Secure Your Spot Now

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALDX Aldeyra Therapeutics	2.2298 of 5 stars	3.5	3.0	0.0	0.0	2.5	2.5	0.0
CALA Calithera Biosciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CSU Capital Senior Living	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
HOOK Hookipa Pharma	3.6887 of 5 stars	3.5	5.0	0.0	0.0	4.0	1.7	1.3

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALDX Aldeyra Therapeutics	3.00	Buy	$9.33	136.89% Upside
CALA Calithera Biosciences	N/A	N/A	N/A	N/A
CSU Capital Senior Living	3.00	Buy	$3,400.00	∞ Upside
HOOK Hookipa Pharma	3.00	Buy	$5.17	507.84% Upside

Current Analyst Ratings

Latest CSU, ALDX, CALA, and HOOK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/3/2024	ALDX Aldeyra Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$10.00
4/2/2024	ALDX Aldeyra Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
3/25/2024	HOOK Hookipa Pharma	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$5.00
3/25/2024	HOOK Hookipa Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.50
1/30/2024	HOOK Hookipa Pharma	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$6.00 ➝ $5.00

(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALDX Aldeyra Therapeutics	N/A	N/A	N/A	N/A	$2.04 per share	N/A
CALA Calithera Biosciences	$9.75M	0.01	N/A	N/A	($0.40) per share	-0.07
CSU Capital Senior Living	$383.86M	0.00	N/A	N/A	($131.19) per share	0.00
HOOK Hookipa Pharma	$20.13M	4.18	N/A	N/A	$0.91 per share	0.93

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALDX Aldeyra Therapeutics	-$37.54M	-$0.64	N/A	N/A	N/A	N/A	-29.45%	-24.24%	5/2/2024 (Estimated)
CALA Calithera Biosciences	-$39.65M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
CSU Capital Senior Living	-$295.37M	$49.78	0.67	N/A	N/A	40.40%	N/A	-5.64%	N/A
HOOK Hookipa Pharma	-$81.58M	-$0.88	N/A	N/A	N/A	-405.28%	-72.30%	-40.51%	5/9/2024 (Estimated)

Latest CSU, ALDX, CALA, and HOOK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/22/2024	Q4 2023	HOOK Hookipa Pharma	-$0.20	-$0.11	+$0.09	N/A	$3.60 million	$7.41 million
3/7/2024	Q4 2023	ALDX Aldeyra Therapeutics	-$0.21	-$0.08	+$0.13	-$0.08	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALDX Aldeyra Therapeutics	N/A	N/A	N/A	N/A	N/A
CALA Calithera Biosciences	N/A	N/A	N/A	N/A	N/A
CSU Capital Senior Living	N/A	N/A	N/A	N/A	N/A
HOOK Hookipa Pharma	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALDX Aldeyra Therapeutics	N/A	6.64	6.64
CALA Calithera Biosciences	N/A	N/A	N/A
CSU Capital Senior Living	N/A	0.11	0.11
HOOK Hookipa Pharma	N/A	3.50	3.50

Ownership

Institutional Ownership

Company	Institutional Ownership
ALDX Aldeyra Therapeutics	59.71%
CALA Calithera Biosciences	N/A
CSU Capital Senior Living	62.65%
HOOK Hookipa Pharma	63.88%

Insider Ownership

Company	Insider Ownership
ALDX Aldeyra Therapeutics	7.30%
CALA Calithera Biosciences	6.60%
CSU Capital Senior Living	5.46%
HOOK Hookipa Pharma	5.82%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ALDX Aldeyra Therapeutics	15	58.90 million	54.60 million	Optionable
CALA Calithera Biosciences	8	4.87 million	4.55 million	Not Optionable
CSU Capital Senior Living	3,416	2.19 million	2.07 million	Optionable
HOOK Hookipa Pharma	56	98.95 million	93.19 million	Optionable

CSU, ALDX, CALA, and HOOK Headlines

Source	Headline
	Buy Rating Affirmed for Hookipa Pharma Amidst Promising Pipeline and Strategic Advancements markets.businessinsider.com - April 24 at 9:08 PM
	HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-700 for the Treatment of KRAS-Mutated Cancers globenewswire.com - April 24 at 7:01 AM
	HOOKIPA Pharma Inc.: HOOKIPA Pharma Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4) finanznachrichten.de - April 17 at 10:29 AM
	HOOKIPA Pharma Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4) finance.yahoo.com - April 16 at 6:51 PM
	Hookipa Pharma Inc (NASDAQ:HOOK) Short Interest Down 5.2% in March americanbankingnews.com - April 16 at 2:30 AM
	HOOKIPA Pharma to Host Investor Call on HB-200 and Planned Path to Registration globenewswire.com - April 10 at 7:01 AM
	Hookipa Pharma Inc (NASDAQ:HOOK) Sees Significant Growth in Short Interest marketbeat.com - April 1 at 8:36 PM
	Optimistic Buy Rating for Hookipa Pharma Based on Promising HB-200 Trial Results and Strategic Trial Design markets.businessinsider.com - March 27 at 8:50 AM
	Hookipa Pharma Inc (NASDAQ:HOOK) Expected to Post FY2028 Earnings of $0.31 Per Share marketbeat.com - March 26 at 8:26 AM
	Hookipa Pharma's (HOOK) "Outperform" Rating Reaffirmed at Royal Bank of Canada marketbeat.com - March 25 at 12:19 PM
	HOOKIPA Pharma Inc.: HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights finanznachrichten.de - March 24 at 5:14 PM
	Time To Worry? Analysts Just Downgraded Their HOOKIPA Pharma Inc. (NASDAQ:HOOK) Outlook finance.yahoo.com - March 24 at 9:19 AM
	HOOKIPA Pharma Stock (NASDAQ:HOOK), Earnings Estimates, EPS, and Revenue benzinga.com - March 23 at 4:51 AM
	Buy Rating Affirmed for Hookipa Pharma on Emerging Oncology and Infectious Disease Pipelines markets.businessinsider.com - March 23 at 4:51 AM
	HOOKIPA Pharma GAAP EPS of -$0.22 misses by $0.02, revenue of $7.41M beats by $2.85M msn.com - March 22 at 9:18 AM
	HOOKIPA Pharma Inc. (HOOK) Reports Q4 Loss, Tops Revenue Estimates zacks.com - March 22 at 9:16 AM
	HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights globenewswire.com - March 22 at 7:01 AM
	HOOKIPA Pharma to Participate in Leerink Partners Global Biopharma Conference globenewswire.com - March 6 at 7:01 AM
	HOOKIPA Pharma Inc HOOK morningstar.com - February 28 at 7:29 PM
	HOOKIPA Pharma Stock (NASDAQ:HOOK) Dividends: History, Yield and Dates benzinga.com - February 22 at 8:00 AM
	HOOKIPA Pharma: Transfer Of Listing cbonds.com - February 3 at 8:48 AM
	All You Need to Know About HOOKIPA Pharma Inc. (HOOK) Rating Upgrade to Strong Buy finance.yahoo.com - February 2 at 2:50 PM
	Maintaining Buy Rating on Hookipa Pharma Amid Strategic Repositioning and Pipeline Promise markets.businessinsider.com - February 1 at 8:55 AM
	Hookipa Pharma Inc (HOOK) uk.investing.com - January 31 at 9:43 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Aldeyra Therapeutics

NASDAQ:ALDX

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.

Calithera Biosciences

NASDAQ:CALA

Calithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.

Capital Senior Living

NYSE:CSU

Capital Senior Living Corp. engages in the operation of senior housing communities. Its senior living options include independent living, assisted living, and memory care. The company was founded in 1990 and is headquartered in Dallas, TX.

Hookipa Pharma

NASDAQ:HOOK

HOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial